Exelixis (EXEL) announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating Cabometyx in combination with Opdivo versus sunitinib for patients with previously untreated advanced renal cell carcinoma. After more than five years of follow-up, the findings demonstrated that efficacy benefits with Cabometyx in combination with Opdivo were sustained long term, the company announced. These results, including subgroup analyses, were presented on February 15 during Oral Abstract Session C: Renal Cell Cancer and Testicular Cancer at the American Society of Clinical Oncology 2025 Genitourinary Cancers Symposium.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis Hold Rating Maintained Amidst Stable Financials and Awaited Trial Data
- Exelixis Earnings Call: Positive Growth and Ambitious Goals
- Exelixis price target raised to $38 from $34 at TD Cowen
- Exelixis price target raised to $36 from $30 at Stifel
- Exelixis price target raised to $29 from $25 at Barclays